BG
GILD icon

Bellevue Group’s Gilead Sciences GILD Stock Holding History

Bellevue Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-600
Closed -$174K – 207
2019
Q1 		$174K Buy
+600
New +$39.9K 0.01% 135

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bellevue Group's GILD Position: Q1 2026 in Review

Bellevue Group increased its Gilead Sciences (GILD) stake by 2,118% in Q1 2026, buying an estimated $156M and bringing the position to 1,169,879 shares worth $163M. The position accounts for 3.88% of the portfolio, ranked #5.

Bellevue Group first reported a position in GILD in Q1 2016 and has held it in 41 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Bellevue Group held 1,169,879 shares of Gilead Sciences worth $163M as of Q1 2026.
  • Bellevue Group bought 1,117,127 Gilead Sciences shares in Q1 2026, an estimated $156M.
  • Gilead Sciences made up 3.88% of Bellevue Group's portfolio in Q1 2026, its #5 holding.
  • Bellevue Group first reported a position in Gilead Sciences in Q1 2016 and has held it in 41 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.